Register for our free email digests:
University of Texas
Latest From University of Texas
Liquid biopsies look set to revolutionize the management of cancer patients. A significant application could come in immuno-oncology, given the rapid uptake of IO drugs and the need to monitor changes in a patient’s immune profile over time to guide therapy selection.
Boehringer Ingelheim's Paola Casarosa explains that when her company partners with academia, it looks for the best way to mine that level of expertise rather than trying to fit the collaboration to a preferred deal model. Plus, our roundup includes three cancer-related deals and one for dry eye disease.
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
Allergan strikes a pair of deals for gastrointestinal and CNS candidates, while Amgen expands its reach in bispecific antibodies via a partnership with Immatics.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.